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Abstract
Background: Data of studies focusing on the trends of adiposity indices among women with prior gestational
diabetes mellitus (GDM), are limited and controversial. The aim of this study was to compare overtime trends of
adiposity indices in women with and without history of GDM, using data of the long term longitudinal population-
based Tehran-Lipid and Glucose-Study (TLGS).
Methods: A total of 3395 eligible women aged (20–50 years), including 801 women with prior history of GDM and
2594 non-GDM controls were recruited from among Tehran-Lipid and Glucose-Study participants. Generalized
estimating equations were applied to assess the time trend of adiposity indices including obesity, central obesity,
body mass index (BMI), lipid accumulation product index (LAP), visceral adiposity index (VAI) and a body shape
index (ABSI) in women with prior GDM and the non-GDM groups after further adjustment for age and BMI.
Results: Median follow-up years for the GDM and non-GDM groups were 12.12 and 11.62 years, respectively. Women
with GDM at initiation had worse adiposity indices than their healthy counterparts. While overall odds of obesity in
women with prior GDM were significantly higher those of the non-GDM groups (OR: 1.35; 95% CI, 1.03–1.7; P = 0.03),
both these groups overtime revealed a positive trend in obesity (P trend < 0.001), an incremental trend which was less
pronounced in GDM women (OR: 0.87; 95% CI, 0.80, 0.95; P interaction = 0.001). Women with prior GDM had higher odds
of central obesity, compared to non-GDM groups (OR: 1.44; 95% CI, 1.06–1.96; P = 0.02) and showed a significant an
incremental trend overtime for both groups (P trend < 0.001 for both) without statistically significant interaction in terms
of their GDM status (P interaction = 0.134). Mean VAI in women with prior GDM was significantly higher than the non-
GDM group (19.7, 95%CI: 6.24, 33.15, P = 0.004), although both groups overtime experienced a negative trend (− 10.9,
95%CI: -13.1, − 2.1, P < 0.001); the GDM group showed a higher decrease in VAI (mean changes: -6.62; 95% CI, − 11,-2.1;
P interaction = 0.001). However overtime there was a positive trend in LAP and ABSI among both women with and
without prior-GDM, though the mean changes were less obvious in women with prior GDM.
Conclusion: Women with prior GDM gained better control of their adiposity than non-GDM women. Nevertheless the
increasing numbers of individuals with GDM and uncontrolled adiposity indices, require prompt attention be paid to
the issue.
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Background
Obesity and gestational diabetes mellitus (GDM), two
major epidemiologic concerns worldwide, in different
age groups, ethnicities and socioeconomic statuses are
increasing worldwide [1]. Obesity as a chronic low-grade
inflammatory disease constitutes an important risk
factor for morbidity and mortality [2], emphasizing the
necessity of the early detection of risk factors and identi-
fication of at risk populations. Women with the history
of GDM are one of these challenging high-risk groups
that influence approximately 2–20% of all pregnancies
[3]. It is well documented that maternal obesity is associ-
ated with GDM, and greater BMI increases the likeli-
hood for insulin therapy later in life [4]. In a recent
study of 22,351 women, each one unit increase of body
mass index (BMI) in pregnancy, increased the odds of
GDM in a subsequent pregnancy [5]. Obese women
enter pregnancy with preexisting insulin resistance (IR)
which worsens with advancing gestation [6, 7]. It has
been shown that insulin-induced glucose transport in
the human skeletal muscle fibers of obese women is sup-
pressed in late pregnancy, and more so in those who de-
velop GDM [8].
Since prior GDM is a well-known risk factor for overt
type 2 diabetes [9], expert international societies recom-
mend the promotion of healthy lifestyles that may affect
adiposity indices in women with this status; increased fat
mass is associated with elevated adipocytokine and
proinflammatory cytokines, insulin resistance, increased
risk of developing adverse outcomes of diabetes,
hypertriglyceridemia, hypercholesterolemia, hyperten-
sion, atherosclerosis, and a higher mortality rate [10].
Several methods are used to assess the content and dis-
tribution of body fat. BMI assessment is commonly used
for evaluation of obesity and prediction of adverse
cardio-metabolic outcomes [11]. Recently some meta-
bolic parameters of lipids were added to adiposity indi-
ces for better prognostic evaluation of cardio-metabolic
adverse events [12]. However, less is known regarding
the subsequent trend of obesity and other complex
adiposity indexes, including lipid accumulation prod-
uct (LAP), visceral adiposity index (VAI), a body
shape index (ABSI) following delivery in women with
a history of GDM, these women are at risk of lifelong
complications, for which they need to be followed
regularly to prevent any adverse events. Considering
the lack of population-based studies and the lack of
evidence about adiposity changes in women with his-
tory of gestational diabetes in comparison to their
normal counterparts, this study aimed to compare the
overtime trend of adiposity indexes in women with and
without history of gestational diabetes mellitus (GDM),
using data of the long term longitudinal population-based
Tehran-Lipid and Glucose-Study (TLGS).
Methods
The ethics committee of the Research Institute for
Endocrine Sciences approved the study and written in-
formed consent was obtained from all subjects before
initiation of the study, which was conducted within the
framework of the TLGS, an observational long term
population-based, ongoing longitudinal study, initiated
in 1998 to evaluate the prevalence and risk factors of
non-communicable diseases in men and women [13];
eventually a total of 15,005 individuals, aged ≥3 years,
were followed every 3 years follow-up, to document data
on demographic, anthropometric, reproductive and
metabolic characteristics, general physical examinations
as well as laboratory measurements. Details of the exam-
inations have previously been published elsewhere [13].
Sample selection
A total of 4076 reproductive aged women, aged 20–50
years, with at least one previous term pregnancy at initi-
ation of the study met the eligibility criteria; of these,
681 (16.7%) women were took part only at the one base-
line visit (without any follow-up visits) were categorized
“lost to follow-up”. Of the remaining 3395 women, 801
(23.6%) women with a history of prior GDM and 2594
(76.4%) without history of GDM, were followed at 3 year
intervals. Of them, 737 (92%) of subjects with GDM,
and 2283 (88%) in the non-GDM group had at least two
follow-up visits. Also, 1894 (73%) and 657 (82%) of the
subjects had at least three follow-up visits in non-GDM
and GDM groups, respectively. The risk of obesity and
central obesity and the trend of all adiposity indices were
assessed overtime in both groups.
Anthropometrics and biochemical measurements
Weight and height were measured, in the standing pos-
ition with participants wearing minimal clothing, by
trained staff using standardized procedures and cali-
brated equipment; WC was measured midway between
the lower rib margin and the iliac-crest at the level of
the umbilicus, at the end of a gentle expiration. Hip cir-
cumference (HC) was measured using an unstreched
measuring tape to the nearest 0.1 cm.
Fasting blood samples were collected after 12 h of fast-
ing (enzymatic colorimetric method, glucose oxidas kit,
Pars Azmoon kit, Iran, inter and intra assay < 2.2%).
Total cholesterol (TC) was measured (enzymatic colori-
metric method with cholesterol esterase and cholesterol
oxidase). HDL-C was assayed after precipitation of the
apolipoprotein B (apo B)-containing lipoproteins with
phosphotungistic acid. TG was assayed using glycerol
phosphate oxidase. Intra- and inter-assay coefficients of
variations for TC, HDL-C, and TG were below 1.9, 3,
and 2.1%, respectively. Analyses were performed using
related kits (Pars Azmon Inc., Tehran, Iran) and a
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Selecta 2 autoanalyzer (Vital Scientific, Spankeren,
Netherlands). To calculate LDL-C, the modified Friede-
wald equation was used [14].
Terms definitions
Since study initiation was in 1998, GDM screening and
diagnosis were based on the World Health Organization
(WHO) screening strategy [15]; hence, all pregnant
women with a negative history of diabetes underwent
the 75-g, 2 h oral glucose tolerance test (OGTT) be-
tween 24 and 28 weeks of gestation. At time of data col-
lection, information was obtained a history of GDM,
using a self-reporting questionnaire. Obesity was defined
as BMI ≥ 30 kg/m2 and central obesity as WC ≥ 90 cm
[16]. Adiposity indexes were calculated using the follow-
ing formula: BMI: [weight (in kilograms) / square of
height (in meters)]; lipid accumulation product (LAP):
[(waist (cm)-58) * TG concentration (mmol/l)] [17]; fe-
male visceral adiposity index (VAI): [WC / 36.58 + (1.89*
BMI) * (TG / 0.81) * (1.52/HDL-C)] (10); a body shape
index (ABSI) = [WC (cm) / [BMI 2/3 * height (m)1/2] [18].
Statistical analysis
Continuous variables were evaluated for normality using
the one sample Kolmogorov-Smirnoff; skewed variables
were log-transformed to normality before data analysis
and are presented as mean or geographic mean (stand-
ard deviation), as appropriate. Categorical variables are
expressed as percentages. Baseline characteristics were
compared between the GDM and non-GDM groups
using the student t test or chi-square test for continuous
or categorical data, respectively. To investigate secular
longitudinal trends of adiposity indices, including obes-
ity, central obesity, BMI, LAP, VAI and ABSI, the gener-
alized estimating equation (GEE) was used. Models for
the examination of time trend were fitted separately for
GDM and non-GDM groups and marginal (age-BMI-ad-
justed) means with P values for trends have been re-
ported for each group. The interaction between the
GDM status and each phase of the study was checked in
a separate model; for this purpose, we entered the
cross-product term (interaction term) in a single model
including both GDM and non-GDM subjects and this
analysis was performed on data of the first follow-up. All
individuals were required to have data on at least one of
the four follow-up visits. Predictors were: time (fol-
low-up years), GDM status, and an interaction of these
two (follow-up years × GDM group). This model was
adjusted for age, BMI, and baseline status of each par-
ameter. Statistical analysis was performed using the soft-
ware package STATA (version 12; STATA Inc., College
station, TX, USA); significance level was set at p < 0.05,
and 95% confidence interval.
Results
The median and interquartile range for follow-up years of
GDM and non-GDM groups were: 12.12 (8.09–13.51) and
11.62 (6.26–13.14), respectively. Baseline characteristics of
the subjects are presented in Table 1. Compared to
non-GDM controls, women with GDM were more likely
to be older, [38.1 (7.9) versus 35.3 (7.8) years (P < 0.001)],
and had significantly higher WC [91.4 (11.5) vs. 86.04
(11.1) cm, P < 0.001], BMI [(29.2 (4.75) vs. 27.3 (4.5)
kg/m2, P < 0.001] and WHR [(0.8 (0.07) vs. 0.8 (0.07),
P < 0.001]. The prevalence of comorbidities of obesity
and central obesity among women with history of GDM
was significantly higher, compared to non-GDM groups
(41.4% vs. 25.4%, P < 0.001) and (56.4% vs. 37%, P < 0.001),
respectively. Moreover, at the beginning of the study, there
were statistically significant differences between the two
groups in terms of lipid profiles of the women, including
total cholesterol, triglycerides, low-density lipoprotein
cholesterol (LDL-C) and high-density lipoprotein choles-
terol (HDL-C) (Table 1). Figure 1 illustrates age-BMI ad-
justed trends of adiposity indices in the GDM and
non-GDM groups. (Fig. 1a-f) While the overall odds of
obesity in women with prior GDM were significantly
higher than the non-GDM group (OR: 1.35; 95% CI, 1.03–
1.7; P = 0.03); both groups demonstrated a positive over-
time trend in obesity (P trend < 0.001), although this incre-
mental trend was less pronounced in GDM women (OR:
0.87; 95% CI, 0.80, 0.95; P interaction = 0.001) (Table 2).
Figure 1 and Table 2 demonstrate approximately the same
findings following comparison of changes in BMI trends
between GDM and the non-GDM groups. Meanwhile,
women with prior GDM had higher odds of central obes-
ity, compared to their non-GDM peers (OR: 1.44; 95% CI,
Table 1 Baseline characteristics of study participants according






Age (years) 38.10 (7.93) 35.31 (7.88) 0.001
BMI (kg/m2) 29.23 (4.75) 27.34 (4.54) 0.001
WC (cm) 91.40 (11.75) 86.04 (11.17) 0.001
WHR 0.85 (0.07) 0.82 (0.07) 0.001
WHtR 0.58 (0.8) 0.55 (0.7) 0.001
Obesity, n (%) 319 (41.4%) 627 (25.4%) 0.001
Central obesity, n (%) 429 (56.4%) 905 (37%) 0.001
TG (mmol/L) a 0.51 (0.55) 0.33 (0.53) 0.001
TC (mmol/L) 5.35 (1.10) 5.14 (1.10) 0.001
LDL-C (mmol/L) 3.40 (0.89) 3.24 (0.91) 0.001
HDL-C (mmol/L) 1.12 (0.28) 1.15 (0.29) 0.001
BMI body mass index, WC waist circumference, WHR waist to hip ratio, WHtR
waist t height ratio, TG triglyceride, TC total cholesterol, LDL-C low-density
lipoprotein cholesterol, HDL-C high-density lipoprotein
aLN, transformed
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1.06–1.96; P = 0.02) (Table 2); central obesity showed a
significant incremental trend over time for both GDM
and non-GDM groups (P trend < 0.001 for both), without
any statistically significant interaction in terms of their
GDM status (P interaction = 0.134). Mean LAP in women
with prior GDM was significantly higher than those in the
non-GDM group (5.96, 95%CI: 1.68, 10.23, P = 0.006). Al-
though women with GDM experienced a non-significant
increase (P trend = 0.064), their non-GDM peers generally
showed a statistically significant increase in their LAP
index (P trend = 0.001); mean changes was less noticeable
in women with prior GDM (mean changes: -0.02; 95% CI,
− 0.04,-0.003; P interaction = 0.023). However, mean VAI in
women with prior GDM was significantly higher than in
the non-GDM group (19.7, 95%CI: 6.24, 33.15, P = 0.004);
however, both groups overtime showed a negative trend
(− 10.9 at each visit, 95%CI: -13.1, − 2.1, P < 0.001), with
the GDM group however showing more decrease (mean
changes: -6.62; 95% CI, − 11,-2.1; P interaction = 0.001). The
overall mean of ABSI in GDM women was 0.07 points
higher than the non-GDM group (95%CI: 0.02–0.12,
P = 0.008). Although overtime a positive trend was
seen in the ABSI in both groups (0.10 per visit,
95%CI: 0.09–0.11, P < 0.001), this increasing trend was
less pronounced in GDM women (mean changes:
-0.02; 95% CI, − 0.04,-0.003; P interaction = 0.023).
Discussion
Our large population-based cohort study, over a decade
long follow-up demonstrated that despite overall higher
obesity, central obesity and adiposity indices in women
with prior GDM compared to their non-GDM counter-
parts, these indices remained more stable in the former
compared to latter who experienced worse changes. Des-
pite higher BMI and worse adiposity indices in women
with a history of GDM, compared to non-GDM ones,
these gaps converge gradually; as seen in controls who
bridged the gap in previous differences of risk profiles
over time.
A wealth of literature supports the association between
GDM and obesity [19, 20], For instance, Ramos et al. in
a retrospective study of 22,658 women reported that the
risk of GDM in obese women was significantly (2-fold)
higher than in their non-obese peers [21]. However, lim-
ited studies have examined the trend of obesity and adi-
posity changes in women with and without GDM over
time. In this respect, Bennett et al. in the Coronary
Fig. 1 Generalized estimating equation (GEE) measures; Mean changes
follow-ups between GDM and non-GDM groups assuming the
interaction between time and the study group and also adjusting for
age, BMI, and baseline parameters. A: obesity, B: central obesity, C: body
mass index, D: lipid accumulation product, E: female visceral adiposity
index, F: a body shape index
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Artery Risk Development in Young Adults (CARDIA)
study compared pre- to post-pregnancy changes in
weight, BMI, WC in women with (n = 137) and without
GDM (n = 1637) during 20 years of follow-up; they
showed that women with GDM had higher pre-pregnancy
weight and BMI, compared to non-GDM ones. While fol-
lowing pregnancy, BMI and weight in both groups of
women with and without GDM increased, pre- to post-
pregnancy changes in body weight, BMI and waist circum-
ference did not differ between these two groups [22].
Indicators of adiposity may be markers for changes in
energy metabolism that influence diabetes and cardiovas-
cular disease progression, and mortality. BMI, a simple in-
dicator of obesity is the most commonly used approach to
characterize obesity in individuals, it however has some
important limitations including a lack of ability to differ-
entiate between fat and muscle mass and not affirming fat
distribution [23]. Among other more accurate measures,
the combined indices of VAI and LAP have been proposed
as valuable indicators of visceral adipose function [17, 24].
VAI is gender-specific indicator based on WC, BMI, TGs,
and HDL and LAP is based on TGs and WC; both are
known to reliably predict insulin resistance and
diabetes mellitus, metabolic syndrome, cardiovascular
events as well as all-cause mortality in non-diabetic
patients [25–27]. These adiposity indicators include
both anthropometric and metabolic parameters that may
indirectly reflect other non-classical risk factors in the de-
velopment of adverse cardio-metabolic events such as al-
tered secretion of adipokines, elevated lipolysis and
plasma free fatty acids, which are not specified by an-
thropometric or metabolic indicators separately [10].
Our findings showed that while LAP and ABSI had an
increasing trend over time, the trend of VAI significantly
Table 2 Estimation of the generalized estimating equation
(GEE) model in women with and without gestational diabetes
mellitus (GDM)




GDM 1.35 (1.03, 1.76) 0.03
Non-GDM Reference – –
Age (years) 0.99 (0.98, 1.01) 0.78
BMI (kg/m2) 1.82 (1.73, 1.91) < 0.001
Baseline obesity 1.85 (1.40, 2.45) < 0.001
Time (years) 1.43 (1.37, 1.49) < 0.001
GDM*Time 0.87 (0.80, 0.95) 0.001
Non-GDM*Time Reference – –
Central obesity
GDM 1.44 (1.06, 1.96) 0.02
Non-GDM Reference – –
Age(years) 1.04 (1.03, 1.05) < 0.001
BMI(kg/m2) 1.36 (1.33, 1.39) < 0.001
Baseline central obesity 2.70 (2.27, 3.21) < 0.001
Time (years) 1.62 (1.53, 1.71) < 0.001
GDM*Time 0.92 (0.82, 1.03) 0.13
Non-GDM*Time Reference – –
BMI
GDM 0.19 (−0.02, 0.41) 0.08
Non-GDM Reference – –
Age(years) -0.02 (−0.03, − 0.01) 0.001
BMI (kg/m2) 0.91 (0.89, 0.92) < 0.001
Time (years) 0.42 (0.39, 0.45) < 0.001
GDM*Time −0.10 (− 0.15, − 0.04) 0.001
Non-GDM*Time Reference – –
LAP
GDM 5.96 (1.68, 10.23) 0.006
Non-GDM Reference – –
Age(years) .39 (.25, .53) < 0.001
BMI (kg/m2) 1.03 (.76, 1.31) < 0.001
Baseline LAP .61 (.58, .64) < 0.001
Time (years) 3.32 (2.61, 4.03) < 0.001
GDM*Time −1.77 (−3.19, −.35) 0.015
Non-GDM*Time Reference – –
VAI
GDM 19.70 (6.24, 33.15) 0.004
Non-GDM Reference – –
Age(years) .75 (.31, 1.18) 0.001
BMI (kg/m2) 2.02 (1.22, 2.81) < 0.001
Baseline VAI .55 (.52, .57) < 0.001
Time (years) −10.94 (−13.18, −8.70) < 0.001
Table 2 Estimation of the generalized estimating equation
(GEE) model in women with and without gestational diabetes
mellitus (GDM) (Continued)
Variables Coefficienta 95% Wald
Confidence Interval
P-Value
GDM*Time −6.62 (−11.07, −2.16) 0.004
Non-GDM*Time Reference – –
ABSI
GDM .07 (.02, .12) 0.008
Non-GDM Reference – –
Age(years) .02 (.01, .02) < 0.001
BMI (kg/m2) −.004 (−.01, −.002) 0.002
Baseline BSI .34 (.31, .36) < 0.001
Time (years) .10 (.09, .11) < 0.001
GDM*Time −.02 (−.04, −.003) 0.023
Non-GDM*Time Reference – –
a Odds Ratio for obesity and central obesity and means for other variables
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decreased in both GDM and non-GDM groups, results
which may highly correlate with the increasing trend of
TG, BMI and WC overtime reported by other studies
[28–30]. In addition, it was shown that WC adjusted for
BMI was increased to a larger extent amongst younger
versus older women [30]. Moreover, based on a formula,
both LAP and ABSI have been directly related to WC
and also have an inverse association with BMI; it is as-
sumed that the effect of BMI is greater in VAI than LAP,
a finding that supports previous evidence demonstrating
that the cut-off points of VAI identifying visceral adipose
dysfunction decrease with age [31]. Our study indicated
that women with prior GDM had significantly higher
BMI at initiation of study, although higher BMI in
women with GDM is decreases overtime most probably
due to the considerable weight loss in GDM group and
weight gain among the non-GDM women; this may be
related to the difference in life style of the subjects.
However, due to certain underlying disturbances in
GDM, which may be further exacerbated by fat accretion
during pregnancy, these women have an increased risk
of obesity, diabetes and other cardio-metabolic diseases
[9]. In a long term follow up study, Minooee et al. re-
ported that the incidence rate of diagnosed diabetes
among women with prior GDM was significantly higher
than in their non-GDM counterparts (9/1000 for women
with GDM and 4/1000 for non-GDM ones). Moreover,
women with prior GDM had shorter median time for
developing diabetes compared to those without GDM
[6.95 years (IQ: 4.22–10.71)] vs, [8.45 years [(IQ: 5.08–
10.89)] [32]. Hence the aforementioned studies and pro-
fessional societies strongly recommend screening, moni-
toring and promotion of lifestyle changes to decrease
the heavy burden of these adverse outcomes in the fu-
ture [28, 33–35]. Increased sensitivity of health care pro-
viders for diabetes surveillance and prevention in
women with prior GDM, may improve the awareness of
these women regarding implementation of lifestyle
changes to prevent diabetes. We assume that women
with prior GDM, as highly selected individuals, are more
likely to modify their lifestyle with various interventions
including diet, exercise and metformin therapy. The
prevalence of obesity, sedentary lifestyle, and nutritional
transition have been growing among the Iranian popula-
tion in the past decade; therefore, the risk of impaired
adiposity indices in women with prior GDM in later life
may be lower than initially anticipated. In this respect,
Ratner et al. showed that metformin and lifestyle inter-
ventions in women with the history of GDM could
steadily decrease weight gain as well as reduce the future
risk of obesity and overt diabetes [35]. However, all
women, regardless of GDM diagnosis experienced an in-
crease in abdominal and visceral adiposity overtime, fol-
lowing pregnancy, which could be associated with a
greater risk of adverse cardio-metabolic outcomes. Our
results additionally highlight the necessity to encourage
all women to make healthy lifestyle modifications follow-
ing after pregnancy.
The main strengths of our study is its methodology as
a long term prospective community-based study with
long follow-up. Low levels of lost to follow-up and pre-
cise measurements of anthropometric and metabolic pa-
rameters are other strengths of this study.
However, this study is limited by investigating only an
Iranian population and cannot be extrapolated to other
population, which emphasizes the need for more cohort
studies in other ethnic populations. Furthermore, GDM
diagnosis was self-reported, which may be limited by re-
call bias, although, the universal screening strategy of
GDM in Iran and subsequent monitoring and treatment
of GDM may restrict this bias. Furthermore, we did not
collect data regarding some lifestyle modifications and
dietary habits; the healthy cohort effect (knowledge
about GDM and paying more attention to themselves)
may have influenced their lifestyle habits, causing desir-
able adiposity status in participants; which led to our op-
timistic findings.
Conclusion
To the best of our knowledge this is one of the pioneer
studies with a long term follow-up to evaluate the impact
of GDM on trends of obesity indices. Its results demon-
strate that despite higher rates of obesity and adiposity in-
dices in women with prior GDM, compared to their
non-GDM counterparts, these additional risks decreases
gradually; women with prior GDM gained better control
of their adiposity than non-GDM women. Nevertheless
the increasing numbers of people with GDM and uncon-
trolled adiposity indices, require prompt attention be paid
to the issue.
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